ER POSITIVE BREAST CANCER
Clinical trials for ER POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ER POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced breast cancer: drug combo trial opens
Disease control Recruiting nowThis early-phase study tests a new drug called OP-1250 (palazestrant) combined with other targeted therapies in people with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find safe doses and check for side effects. About 190 adults will joi…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC
-
New hope for advanced breast cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug, palazestrant, combined with ribociclib against the standard letrozole with ribociclib for people with ER+, HER2- advanced breast cancer that has not been treated before. About 1,000 adults with locally advanced or metastatic breast cancer will take pa…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 17, 2026 12:06 UTC
-
New drug combo aims to wipe out breast cancer before surgery
Disease control Recruiting nowThis study tests whether giving a combination of three drugs (neratinib, hormone therapy, and trastuzumab) for 24 weeks before surgery can eliminate all signs of cancer in the breast for people with a specific type of breast cancer (ER-positive, HER2-positive). About 30 postmenop…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Ruth O'Regan • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New drug aims to stop breast cancer spread before it starts
Disease control Recruiting nowThis study tests a drug called elacestrant in people with ER+/HER2- breast cancer whose blood tests show cancer DNA (ctDNA) but no clear spread. About 220 participants will either get elacestrant or continue their current hormone therapy. The goal is to see if elacestrant can del…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New hope for advanced breast cancer: OP-1250 faces off against standard care
Disease control Recruiting nowThis study tests a new drug called OP-1250 (palazestrant) against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can slow cancer growth better than standard care. The…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC
-
Can a drug holiday make breast cancer treatment work again?
Disease control Recruiting nowThis study is for people with a common type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to a standard treatment called a CDK4/6 inhibitor. The researchers want to see if taking a break from that drug and then switching to a different combina…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC
-
Promising combo aims to stall advanced breast cancer
Disease control Recruiting nowThis study tests whether adding everolimus to elacestrant can help people with a certain type of advanced breast cancer (ER+/HER2- with an ESR1 mutation) live longer without their cancer getting worse. About 240 adults whose cancer has stopped responding to standard hormone thera…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC